Skip to Main Content

For the first time, a New York state panel will review a prescription drug over concerns it may cause the state Medicaid program to exceed a cap on drug spending. Such reviews were greenlighted under a law passed last year in a bid to control rising prices for medicines.

At issue is a cystic fibrosis drug called Orkambi, which is sold by Vertex Pharmaceuticals (VRTX). A drug utilization review board is scheduled to meet on April 26 and, depending upon the outcome, could recommend a supplemental rebate to lower the cost to the program.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!